{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dacarbazine+%28DTIC%29&page=2", "query": { "intervention": "Dacarbazine (DTIC)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 707, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dacarbazine+%28DTIC%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dacarbazine+%28DTIC%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T10:30:46.338Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00669669", "title": "O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "In Vitro-Treated Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "O6-Benzylguanine", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Proton Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-02-25", "completion_date": "2021-01-20", "has_results": true, "last_update_posted_date": "2022-05-18", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669669" }, { "nct_id": "NCT00327600", "title": "Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "imexon", "type": "DRUG" }, { "name": "DTIC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AmpliMed Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2005-07", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2010-09-15", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00327600" }, { "nct_id": "NCT00436436", "title": "O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "O6-benzylguanine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 12, "start_date": "2006-11-13", "completion_date": "2010-04-14", "has_results": true, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436436" }, { "nct_id": "NCT05095376", "title": "Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Lomustine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Photon Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 265, "start_date": "2022-03-28", "completion_date": "2031-02-12", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 418, "location_summary": "Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05095376" }, { "nct_id": "NCT05922904", "title": "PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-12-14", "completion_date": "2027-10-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05922904" }, { "nct_id": "NCT00311584", "title": "Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 59, "start_date": "2006-04", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-09-30", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 96 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00311584" }, { "nct_id": "NCT01189643", "title": "Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Sarcoma", "Desmoplastic Small Round Cell Tumor (DSRCT)" ], "interventions": [ { "name": "irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "29 Years", "sex": "ALL", "summary": "1 Year to 29 Years" }, "enrollment_count": 15, "start_date": "2010-08", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189643" }, { "nct_id": "NCT01891747", "title": "A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2013-07", "completion_date": "2022-01-31", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01891747" }, { "nct_id": "NCT00003647", "title": "Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IV Melanoma", "Stage III Melanoma", "Recurrent Melanoma" ], "interventions": [ { "name": "allovectin-7", "type": "DRUG" }, { "name": "allovectin-7/dacarbazine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vical", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": null, "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-07", "completion_date": "2002-09", "has_results": false, "last_update_posted_date": "2008-07-25", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 44, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Encinitas, California + 39 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003647" }, { "nct_id": "NCT00005955", "title": "Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": "2002-09", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-10-07T10:30:46.338Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005955" } ] }